P502 Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study

Suppressor of Tumorigenicity 2 (ST2) is an IL33 receptor detected in mucosa and serum of ulcerative colitis (UC) patients. We aimed to evaluate soluble ST2 (sST2) as a surrogate biomarker of disease activity and therapeutic response in subjects with moderately to severely active UC under golimumab and to compare with standard biomarkers such as faecal calprotectin (FC) and C-reactive protein (CRP). Open-label single-arm multi-centre prospective...